mms evan picard

Evan’s leadership journey has seen him play pivotal roles in shaping business strategies across multiple industries. Before joining MMS, Evan was Vice President of Finance at Parexel, having previously made significant contributions to renowned entities such as Syneos Health, PRA Health Sciences, and RTI International. His ability to forge strong teams and provide forward-looking insights positions him as a cornerstone of MMS’s future growth.

As Chief Financial Officer of MMS, Evan serves as the global head of the Accounting, Finance, Human Resources, and Talent Acquisition functions. Evan and his team are responsible for: financial planning and analysis, consolidations under US GAAP, treasury, HR leadership, and recruiting services. Evan’s role underscores MMS Holdings’ commitment to top-tier financial stewardship, talent development, and MMS’ growth-oriented mindset. His unique blend of experience and acumen promises to steer the company toward continued financial success.

What we have here at MMS is very special. We have great staff who deliver day in and day out for our clients and our organization. The expertise we bring to the market is top tier, and it shows through our customer satisfaction scores and our customer retention rates. In my organization, we aim to provide high quality services and solutioning for our internal and external partners. My team accomplishes this by exemplifying our corporate values, like “Wow the Customer” and “SOUL” (Sense Of Urgency Leadership). I’m very proud of the work we do at MMS and I’m excited to continue on our journey of evolution and growth as a company delivering value to our clients and bringing new therapies to patients swiftly and creatively.
Evan Picard
Chief Financial Officer

Evan has a BS – Management degree from Virginia Tech (Pamplin College of Business) and an MBA from the College of William & Mary (Mason School of Business).

Suggested For You

news

April 3rd, 2025

Datacise by MMS Wins 2025 Data Breakthrough Award for Best Data Science Solution

perspectives

March 27th, 2025

Enhancing Drug Safety Through Digital Solutions: Innovative Technologies in FDA REMS Programs

news

March 19th, 2025

MMS REMS-focused Technology bolsters Full-Service REMS Solutions

webinar

April 30th, 2025

Advancing Clinical Development with Innovative Trial Design and Regulatory Strategies

perspectives

March 6th, 2025

Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products

webinar

March 25th, 2025

Overcoming NDA/BLA Submission Challenges: Practical Strategies for Success

perspectives

February 13th, 2025

Helping European Drug Development Companies Succeed in the US Market

news

February 12th, 2025

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

perspectives

January 30th, 2025

Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned

perspectives

January 21st, 2025

REMS Modifications and Revisions: A Retrospective from the Past 12 Months

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development

regulatory intelligence

January 17th, 2025

New FDA Protocol Deviation Guidance:  Planning for the Things That Don’t Go According to Plan